Drug development and industrial pharmacy · 2026
Reformulating rofecoxib: targeted nanostructured lipid carrier gel for localized treatment of rheumatoid arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gangurde Sanket, Aher Abhijeet A, Gujarathi Nayan A, Patil Tulshidas S, Aher Kiran B
Аннотация
OBJECTIVE: This study aimed to develop and evaluate nanostructured lipid carrier (NLC) gel loaded with rofecoxib (ROX) for topical treatment of rheumatoid arthritis (RA), minimizing systemic exposure and cardiotoxicity.
SIGNIFICANCE: Despite its withdrawal due to cardiovascular risk, ROX remains a potent COX-2 inhibitor. Reformulating it into a localized NLC delivery system could enable safe therapeutic application in RA by targeting inflamed joints with minimal systemic effects.
METHOD: A Box-Behnken design optimized lipid content, surfactant concentration, and sonication time to achieve minimal particle size, high entrapment efficiency, and stable zeta potential. The optimized formulation was incorporated into a gel and evaluated for physicomechanical properties, drug release, and in vivo performance in a complete Freund's adjuvant (CFA)-induced arthritic rat model. Radiographic, histopathological, and biodistribution studies were conducted.
RESULTS: Optimized ROX-NLCs exhibited particle size of 225 nm, entrapment efficiency of 90.65%, PDI of 0.265, and zeta potential of -38 mV, with good stability and gel compatibility. In vitro drug release followed Higuchi and Korsmeyer-Peppas kinetics, showing higher cumulative release compared to plain ROX gel and oral ROX. In vivo, ROX-NLC gel significantly reduced paw swelling and arthritis scores, preserved joint architecture, and avoided cardiac alterations observed with oral ROX. Biodistribution confirmed negligible systemic drug levels (below LOD: 0.079 µg/mL).
CONCLUSION: ROX-NLCs gel provides a safe, sustained, and effective topical delivery system for RA therapy, enhancing local efficacy while reducing systemic cardiotoxic risk.
SIGNIFICANCE: Despite its withdrawal due to cardiovascular risk, ROX remains a potent COX-2 inhibitor. Reformulating it into a localized NLC delivery system could enable safe therapeutic application in RA by targeting inflamed joints with minimal systemic effects.
METHOD: A Box-Behnken design optimized lipid content, surfactant concentration, and sonication time to achieve minimal particle size, high entrapment efficiency, and stable zeta potential. The optimized formulation was incorporated into a gel and evaluated for physicomechanical properties, drug release, and in vivo performance in a complete Freund's adjuvant (CFA)-induced arthritic rat model. Radiographic, histopathological, and biodistribution studies were conducted.
RESULTS: Optimized ROX-NLCs exhibited particle size of 225 nm, entrapment efficiency of 90.65%, PDI of 0.265, and zeta potential of -38 mV, with good stability and gel compatibility. In vitro drug release followed Higuchi and Korsmeyer-Peppas kinetics, showing higher cumulative release compared to plain ROX gel and oral ROX. In vivo, ROX-NLC gel significantly reduced paw swelling and arthritis scores, preserved joint architecture, and avoided cardiac alterations observed with oral ROX. Biodistribution confirmed negligible systemic drug levels (below LOD: 0.079 µg/mL).
CONCLUSION: ROX-NLCs gel provides a safe, sustained, and effective topical delivery system for RA therapy, enhancing local efficacy while reducing systemic cardiotoxic risk.